Donate
Donate

Molecular Ophthalmology
Laboratory

Request More Information

The Molecular Ophthalmology Laboratory at the Retina Foundation is dedicated to advancing treatments for retinal diseases through cutting-edge molecular research.

The lab focuses on understanding the underlying mechanisms of age-related macular degeneration (AMD) and other vision-threatening conditions, with the goal of developing innovative therapies to preserve and restore sight.

Dr. Karl Csaky, and his team leverage the latest advancements in molecular biology, gene therapy and regenerative medicine to translate scientific discoveries into clinical solutions that improve patient outcomes.

If you are interested in participating or if you would like more information, please contact our AMD clinical research staff at amd@retinafoundation.org or 214.363.3911, ext. 400.

Generations of our family trust our vision to Dr. Csaky, starting with my father, Herbert Hunt and my aunt, Caroline Rose Hunt. AMD runs in our family, and we are fortunate that we have a world-renowned expert in AMD right here at home. My family’s patient experience is beyond compare.
Libby Allred
I am both a patient of Dr. Csaky and a supporter of the Retina Foundation. We’re fortunate to have a world-renowned expert like Dr. Csaky right here in Dallas who is leading the way for innovative research to find new solutions for retinal diseases. My vision has improved under his care, and I know he provides hope for many others as well.
Steve Durham
CLINICAL STUDY

How To Participate

Anyone who has a diagnosis of AMD and is over the age of 18 years old is welcome to participate in the research studies being conducted at the Retina Foundation. An initial screening process will determine eligibility for participation in one of our AMD studies.

Your participation in a clinical trial is the most valuable contribution you can make towards the development of future treatment options. Dr. Karl Csaky’s team will meet with you to review your eligibility, possible risks, benefits, and the details of participating in a specific trial.

Our multidisciplinary team conducts various types of research to:

  • Better understand AMD
  • Develop ways to slow progression of the disease
  • Discover better treatment options

We participate in studies funded by pharmaceutical companies, the National Eye Institute and our own investigator-initiated studies.

If you are interested in participating in a clinical trial for AMD, please email  amd@retinafoundation.org or 214.363.3911, ext. 139.

Experts

Karl Csaky, MD, PhD

Chief Executive and Medical Officer
T. Boone Pickens Director
Clinical Center of Innovation for AMD

Doris Lambracht-Washington, PhD

Senior Staff Scientist

Sanchareeka Dey, PhD

Clinical Staff Scientist

Alison Takacs, MS

Staff Scientist

Neha Tandon, PhD

Clinical Staff Scientist

Jessica Clark

Sr. Clinical Research Coordinator

Katherine Juroch, MS

Clinical Research Coordinator

Paige Grona Kennedy

Patient Coordinator and Outreach Manager

Natalia Feliz

Clinical Research Coordinator

Cindy Baillie

Manager of Clinic Staff

Dhiraj Dokwal, PhD

Staff Scientist

Shelby Crookall

Ophthalmic Technician

Shelby Crookall

Ophthalmic Technician

Eli Trauner

Clinic Assistant

CLINICAL STUDIES

Current Enrollments

NCT#: 05019521

Alexion

A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
More Information
NCT#: 03972709

Genentech GR42558

A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO)
More Information
NCT#: 04615325

Genentech GR42163

A Phase Ia Multicenter, Open -Label, Single Dose, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogencity of Intravitreal Injections of RO7303359 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
More Information
NCT#: 04566445

Gyroscope Horizon

A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
More Information
NCT#: 03364153

Ophthotech OPH2005

A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
More Information
NCT#: 03815825

Ionis Golden

A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
More Information

Get the Latest Updates

Sign up to receive the “Recently @Retina” newsletter to keep up-to-date.